These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38617062)

  • 1. Trends in use of composite endpoints in clinical trials: A comparison between acute heart failure trials and COVID-19 trials.
    Shi L; Lindsell CJ; Liu D
    J Clin Transl Sci; 2024; 8(1):e55. PubMed ID: 38617062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Composite endpoints in COVID-19 randomized controlled trials: a systematic review.
    Martins PN; Lourenço MHT; Mota GPS; Cavalcanti AB; Peçanha Antonio AC; Diaz-Quijano FA
    Clin Trials; 2024 Oct; ():17407745241276130. PubMed ID: 39390767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The maraca plot: A novel visualization of hierarchical composite endpoints.
    Karpefors M; Lindholm D; Gasparyan SB
    Clin Trials; 2023 Feb; 20(1):84-88. PubMed ID: 36373800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.
    Anker SD; Schroeder S; Atar D; Bax JJ; Ceconi C; Cowie MR; Crisp A; Dominjon F; Ford I; Ghofrani HA; Gropper S; Hindricks G; Hlatky MA; Holcomb R; Honarpour N; Jukema JW; Kim AM; Kunz M; Lefkowitz M; Le Floch C; Landmesser U; McDonagh TA; McMurray JJ; Merkely B; Packer M; Prasad K; Revkin J; Rosano GM; Somaratne R; Stough WG; Voors AA; Ruschitzka F
    Eur J Heart Fail; 2016 May; 18(5):482-9. PubMed ID: 27071916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: renal endpoints.
    McIlroy DR; Bellomo R; Billings FT; Karkouti K; Prowle JR; Shaw AD; Myles PS
    Br J Anaesth; 2018 Nov; 121(5):1013-1024. PubMed ID: 30336845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
    Bakal JA; Westerhout CM; Armstrong PW
    Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials.
    Brown PM; Rogne T; Solligård E
    Pharm Stat; 2021 Mar; 20(2):413-417. PubMed ID: 32893957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.
    Gasparyan SB; Buenconsejo J; Kowalewski EK; Oscarsson J; Bengtsson OF; Esterline R; Koch GG; Berwanger O; Kosiborod MN
    Ther Innov Regul Sci; 2022 Sep; 56(5):785-794. PubMed ID: 35699910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment.
    Samman Tahhan A; Vaduganathan M; Greene SJ; Okafor M; Kumar S; Butler J
    Curr Heart Fail Rep; 2018 Feb; 15(1):10-16. PubMed ID: 29350324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints.
    Rauch G; Kieser M; Binder H; Bayes-Genis A; Jahn-Eimermacher A
    Clin Res Cardiol; 2018 May; 107(5):437-443. PubMed ID: 29453594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
    Kristensen AMD; Bovin A; Zwisler AD; Cerquira C; Torp-Pedersen C; Bøtker HE; Gustafsson I; Veien KT; Thomsen KK; Olsen MH; Larsen ML; Nielsen OW; Hildebrandt P; Foghmar S; Jensen SE; Lange T; Sehested T; Jernberg T; Atar D; Ibanez B; Prescott E
    Trials; 2020 May; 21(1):415. PubMed ID: 32446298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some issues with composite endpoints in clinical trials.
    Chi GY
    Fundam Clin Pharmacol; 2005 Dec; 19(6):609-19. PubMed ID: 16313272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New composite endpoints to assess efficacy in periodontal therapy clinical trials.
    Lynch SE; Lavin PT; Genco RJ; Beasley WG; Wisner-Lynch LA
    J Periodontol; 2006 Aug; 77(8):1314-22. PubMed ID: 16881800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information.
    von Cube M; Grodd M; Wolkewitz M; Hazard D; Wengenmayer T; Canet E; Lambert J
    Crit Care Med; 2021 Jan; 49(1):e11-e19. PubMed ID: 33148952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Composite endpoints, including patient reported outcomes, in rare diseases.
    Verbeeck J; Dirani M; Bauer JW; Hilgers RD; Molenberghs G; Nabbout R
    Orphanet J Rare Dis; 2023 Sep; 18(1):262. PubMed ID: 37658423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical perspectives on the use of composite endpoints.
    Cannon CP
    Control Clin Trials; 1997 Dec; 18(6):517-29; discussion 546-9. PubMed ID: 9408715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
    Zannad F; Garcia AA; Anker SD; Armstrong PW; Calvo G; Cleland JG; Cohn JN; Dickstein K; Domanski MJ; Ekman I; Filippatos GS; Gheorghiade M; Hernandez AF; Jaarsma T; Koglin J; Konstam M; Kupfer S; Maggioni AP; Mebazaa A; Metra M; Nowack C; Pieske B; Piña IL; Pocock SJ; Ponikowski P; Rosano G; Ruilope LM; Ruschitzka F; Severin T; Solomon S; Stein K; Stockbridge NL; Stough WG; Swedberg K; Tavazzi L; Voors AA; Wasserman SM; Woehrle H; Zalewski A; McMurray JJ
    Eur J Heart Fail; 2013 Oct; 15(10):1082-94. PubMed ID: 23787718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.